ME00376B - DIHIDROPTERIDINONI, POSTUPAK ZA NJlHOVO PRIPREMANJE I NJlHOVA PRIMJENA KAO LIJEK - Google Patents
DIHIDROPTERIDINONI, POSTUPAK ZA NJlHOVO PRIPREMANJE I NJlHOVA PRIMJENA KAO LIJEKInfo
- Publication number
- ME00376B ME00376B MEP-2008-588A MEP58808A ME00376B ME 00376 B ME00376 B ME 00376B ME P58808 A MEP58808 A ME P58808A ME 00376 B ME00376 B ME 00376B
- Authority
- ME
- Montenegro
- Prior art keywords
- group
- alkyl
- denotes
- aryl
- given case
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract 5
- 238000000034 method Methods 0.000 title claims abstract 3
- 229940079593 drug Drugs 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- -1 piperazinylcarbonyl Chemical group 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000005974 C6-C14 arylcarbonyl group Chemical group 0.000 claims 2
- 229910003204 NH2 Inorganic materials 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005592 polycycloalkyl group Polymers 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Ovaj pronalazak odnosi se, na nove dihidropteridinone, opšte formule (I), pri čemu ostaci L, R 1 , R 2 , R 3 , R 4 i R 5 imaju značenja navedena u patentnim zahtevima i u opisu, na njihove izomere, na postupak za pripremanje ovih dihidropteridinona, kao i na njihovu primenu kao lekova.
Claims (12)
1.Jedinjenja opšte formule (I), u kojoj R1, R2, koji mogu biti isti ili različiti, označavaju vodonik ili, u datom slučaju, supstituisanu C1-C6-alkil grupu, ili R1 i R2, zajedno označavaju, 2- do 5-člani alkil most, koji može da sadrži 1 do 2 heteroatoma, R3 označava vodonik ili ostatak odabran iz grupe koju čine, u datom slučaju, supstituisana C1-C12-alkil, C1-C12-alkenil, C1-C12-alkinil i C6-C14-aril grupa, ili ostatak odabran iz grupe koju čine, u datom slučaju, supstituisana i/ili premošćavajuća C3-C12-cikloalkil, C3-C12-cikloalkenil, C7-C 12-policikloalkil, C7-C12-policikloalkenil, C5-C12-spirocikloalkil grupa, C3-C12-heterocikloalkil grupa koja sadrži 1 do 2 heteroatoma, i C3-C12-heterocikloalkenil grupa koja sadrži 1 do 2 heteroatoma, ili R1 i R3, ili R2 i R3, zajedno, označavaju zasićen ili nezasićen C3-C4-alkil most, koji može da sadrži 1 heteroatom, R4 označava ostatak odabran od, vodonika, -CN, hidroksi, -NR6R7 grupe i halogena, ili ostatak odabran iz grupe koju čine, u datom slučaju, supstituisana C1-C6-alkil, C2-C6-alkenil, C2-C6-alkinil, C1-C5-alkiloksi, C2-C5-alkeniloksi, C2-C5-alkiniloksi, C1-C6-alkiltio, C1-C6-alkilsulfokso i C1-C6-alkilsulfonil grupa, L označava veznu grupu odabranu iz grupe koju čine, u datom slučaju, supstituisana C2-C10-alkil, C2-C10-alkenil, C6-C14-aril, -C2-C4-alkil-C6-C14-aril, -C6-C14-aril-C1-C4-alkil, u datom slučaju, premošćavajuća C3-C12-cikloalkil grupa i heteroaril grupa, koja sadrži 1 ili 2 atoma azota, n označava 0 ili 1 m označava 1 ili 2 R5 označava ostatak odabran iz grupe koju čine, u datom slučaju, supstituiana morfolinil, piperidinil, piperazinil, piperazinilkarbonil, pirolidinil, tropenil, R8-diketo-metilpiperazinil, sulfoksomorfolinil, sulfonilmorfolinil, tiomorfolinil, -NR8R9 i azacikloheptil grupa, R6, R7, koji mogu biti isti ili različiti, označavaju vodonik ili C1-C4-alkil grupu, a R8, R9 označavaju nesupstituisane azotne supstituente na R5, koji mogu biti isti ili različiti, ili vodonik ili ostatak odabran iz grupe koju čine C1 -C6-alkil, -C1 -C4-alkil-C3-C10-cikloalkil, C3-C10-cikloalkil, C6 -C14-aril,-C1 -C4-alkil-C6-C14-aril, piranil, piridinil, pirimidinil, C1 -C4-alkiloksikarbonil, C6 -C14- alkilkarbonil, C1 -C4-alkilkarbonil, C6-C14-arilmetiloksikarbonil, C6-C14-arilsulfonil, C1 -C4-alkilsulfonil- i C6-C14-aril-C1 -C4-alkilsulfonil- grupa, u datom slučaju, u obliku svojih tautomera, svojih racemata, svojih enantiomera, svojih dijastereomera i svojih smeša, kao i, u datom slučaju, svojih farmakološki prihvatljivih adicionih soli sa kiselinom. 1.Jedinjenja opšte formule (I), u kojoj R1 do R4, R6 i R7 imaju prethodno navedena značenja, a L označava veznu grupu, odabranu iz grupe koju čine, u datom slučaju, supstitui-sana C2-C10-alkil, C2-C10-alkenil, C6-C14-aril, -C2-C4-alkil-C6-C14aril, -C6-C14-aril-C1-C4-alkil grupa, u datom slučaju, premošćavajuća C3-C12-cikloalkil grupa i heteroaril grupa, koja sadrži 1 ili 2 atoma azota, n označava 1 m označava 1 ili 2 R5 označava ostatak koji je preko atoma azota vezan za L, odabran iz grupe koju čine, u datom slučaju, supstituisana morfolinil, piperidinil, R8-piperazinil, pirolidinil, tropenil, R8-diketometilpiperazinil, sulfoksomorfolinil, sulfonilmorfolinil, tiomorfolinil, -NR8R9 i azacikloheptil grupa, R8, R9 označavaju nesupstituisane azotne supstituente na R5, koji mogu biti isti ili različiti, vodonik ili ostatak izabran iz grupe koju čine, C1-C6-alkil, -C1-C4-alkil-C3-C10-cikloalkil, C3-C10-cikloalkil, C6-C14-aril, -C1-C4-alkil-C6-C14-aril, piranil, piridinil, pirimidinil, C1-C4-alkiloksikarbonil, C6-C14-arilkarbonil, C1-C4-alkilkarbonil, C6-C14-arilmetiloksikarbonil, C6-C14-arilsulfo-nil, C1-C4-alkilsulfonil i C6-C14-aril-C1-C4-alkilsulfonil grupa, u datom slučaju, u obliku svojih tautomera, svojih racemata, svojih enantiomera, svojih dijastereomera i svojih smeša, kao i, u datom slučaju, svojih farmakološki prihvatljivih adicionih soli sa kiselinom.
2. Jedinjenja prema zahtevu 1, u kojima R1 do R4, R6 i R7 imaju prethodno navedena značenja, L označava veznu grupu, odabranu iz grupe koju čine, u datom slučaju, supstitui-sana C2-C10-alkil, C2-C10-alkenil, C6-C14-aril, -C2-C4-alkil-C6-C14-aril, -C6-C14-aril-C1-C4-alkil, u datom slučaju, premošćavajuća C3-C12-cikloalkil grupa i heteroaril grupa koja sadrži 1 ili 2 atoma azota, n označava 0 ili 1 m označava 1 ili 2 R5 označava grupu koja je preko atoma ugljenika vezana za L, odabranu iz grupe koju čine, R -piperidinil, R R -piperazinil, R -pirolidinil, R -piperazinilkarboml, R -trope-nil, R8-morfolinil i R8-azacikloheptil grupa, a R8, R9 označavaju nesupstituisane azotne supstituente na R5, iste ili različite, vodonik ili ostatak odabran iz grupe koju čine C1-C6-alkil, -C1 -C4-alkil-C3-C10-cikloalkil, C3-C10-cikloalkil, C6-C14-aril, -C1 -C4-alkil-C6-C14-aril, piranil, piridinil, pirimidinil, C1 -C4-alkiloksikarbonil, C6-C14-arilkarbonil, C1-C4-alkilkarbonil, C6-C14-arilmetiloksikarbonil, C6-C14-arilsulfo-nil, C1-C4-alkilsulfonil i C6-C14-aril-C1-C4-alkilsulfonil grupa, u datom slučaju, u obliku svojih tautomera, svojih racemata, svojih enantiomera, svojih dijastereomera i svojih smeša, kao i, u datom slučaju, svojih farmakološki prihvatljivih adicionih soli sa kiselinom.
3. Jedinjenja, prema nekom od zahteva 1 do 3, u kojima L, m, n i R3 do R9 imaju prethodno navedena značenja, a R1, R2, isti ili različiti, označavaju ostatak izabran iz grupe koju čine, vodonik, Me, Et, Pr, ili R1 i R2 zajedno obrazuju C2-C4-alkil most, u datom slučaju, svojih tautomera, svojih racemata, svojih enantiomera, svojih dijastereomera, i svojih smeša, kao i, u datom slučaju, svojih farmakološki prihvatljivih adicionih soli sa kiselinom.
4.Jedinjenja, prema nekom od zahteva 1 do 4, u kojima R1, R2, m, n i R5 do R8, imaju prethodno navedena značenja, a R3 označava ostatak izabran iz grupe koju čine, u datom slučaju, supstituisana C1-C10-alkil, C3-C7-cikloalkil, C3-C6-heterocikloalkil i C6-C14-aril grupa, ili R1 i R3, ili R2 i R3, zajedno označavaju zasićen ili nezasićen C3-C4-alkil most, koji može da sadrži 1 do 2 heteroatoma, R4 označava ostatak izabran iz grupe koju čine, vodonik, OMe, OH, Me, Et, Pr, OEt, NHMe, NH2, F, Cl, Br, O-propargil, O-butinil, CN, SMe, NMe2, CONH2, etinil, propinil, butinil i alil grupa, a L označava veznu grupu odabranu iz grupe koju čine, u datom slučaju, supstituisana fenil, fenilmetil, cikloheksil i razgranata C1-C6-alkil grupa, u datom slučaju, u obliku svojih tautomera, svojih racemata, svojih enantiomera, svojih dijastereomera i svojih smeša, kao i, u datom slučaju, svojih farmakološki prihvatljivih adicionih soli sa kiselinom.
5. Jedinjenja, prema nekom od zahteva 1 do 4, u kojima R1, R2, m, n i R5 do R8, imaju prethodno navedena značenja, a R3 označava ostatak izabran iz grupe koju čine, u datom slučaju, supstituisana C1-C10-alkil, C3-C7-cikloalkil, C3-C6-heterocikloalkil i C6-C14-aril grupa, ili R1 i R3, ili R2 i R3, zajedno označavaju zasićen ili nezasićen C3-C4-alkil most, koji može da sadrži 1 do 2 heteroatoma, R4 označava ostatak izabran iz grupe koju čine, vodonik, OMe, OH, Me, Et, Pr, OEt, NHMe, NH2, F, Cl, Br, O-propargil, O-butinil, CN, SMe, NMe2, CONH2, etinil, propinil, butinil i alil grupa, a L označava veznu grupu odabranu iz grupe koju čine, u datom slučaju, supstituisana fenil, fenilmetil, cikloheksil i razgranata C1-C6-alkil grupa, u datom slučaju, u obliku svojih tautomera, svojih racemata, svojih enantiomera, svojih dijastereomera i svojih smeša, kao i, u datom slučaju, svojih farmakološki prihvatljivih adicionih soli sa kiselinom.
6. Jedinjenje formule I, prema nekom od zahteva 1 do 5, koje se koristi kao lek.
7. Jedinjenje formule I, prema nekom od zahteva 1 do 5, koje se koristi kao lek sa antiproliferativnim dejstvom.
8. Upotreba jedinjenja formule I, prema nekom od zahteva 1 do 5, za pripremanje leka za lečenje i/ili prevenciju raka, infekcija, zapaljenskih i autoimunskih oboljenja.
9. Postupak za lečenje i/ili prevenciju, raka, infekcija, zapaljenskih i autoimunskih oboljenja, naznačen time, što se pacijentu daje efikasna količina jedinjenja formule I, prema zahtevu 1 do 4.
10. Farmaceutski preparat, koji sadrži kao delotvornu supstancu jedno ili više jedinjenja, opšte formule (I), prema nekom od zahteva 1 do 4, ili njihovih farmakološki podnošljivih soli, u datom slučaju, sa uobičajenim pomoćnim sredstvima i/ili nosačima.
11. Postupak za pripremanje jedinjenja opšte formule (I), u kojoj R1-R5, m, n i L imaju značenje navedeno u zahtevima 1 do 5, naznačen time, što jedinjenje opšte formule (II) u kojoj R1-R3 imaju značenje navedeno u zahtevima 1 do 4, a A je grupa koja se odvaja, reaguje sa, u datom slučaju, supstituisanim jedinjenjem opšte formule (III), u kojoj R4 ima značenje navedeno u zahtevima 1 do 5, a R10 označava, OH, NH-L-R5, -O-metil, -O-etil grupu, pa zatim, u datom slučaju, proizvod opšte formule (IV) u kojoj R1 do R4 imaju značenje navedeno u zahtevima 1 do 5, a R10 označava OH, -NH-L-R5, -O-metil ili -O-etil grupu, u datom slučaju, posle prethodne hidrolize estarske grupe -COR10, reaguje sa nekim aminom, opšte formule (V) NH2-L-R5m (V) u kojoj R5 ima značenje navedeno u zahtevima 1 do 5.
12. Jedinjenje formule (II) u kojoj R1-R3 imaju značenje navedeno u zahtevima 1 do 5, a A je grupa koja se odvaja.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2003/001935 WO2004076454A1 (de) | 2003-02-26 | 2003-02-26 | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MEP58808A MEP58808A (en) | 2011-05-10 |
| ME00376B true ME00376B (me) | 2011-10-10 |
Family
ID=32921552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-588A ME00376B (me) | 2003-02-26 | 2003-02-26 | DIHIDROPTERIDINONI, POSTUPAK ZA NJlHOVO PRIPREMANJE I NJlHOVA PRIMJENA KAO LIJEK |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1599478B1 (me) |
| JP (1) | JP3876265B2 (me) |
| KR (1) | KR100983462B1 (me) |
| CN (2) | CN100537570C (me) |
| AT (1) | ATE361924T1 (me) |
| AU (1) | AU2003215591B2 (me) |
| BR (1) | BR0318145A (me) |
| CA (1) | CA2517020C (me) |
| CY (1) | CY1106752T1 (me) |
| DE (1) | DE50307267D1 (me) |
| DK (1) | DK1599478T3 (me) |
| EA (1) | EA008778B1 (me) |
| ES (1) | ES2287583T3 (me) |
| HR (1) | HRP20050735B1 (me) |
| IL (1) | IL170419A (me) |
| ME (1) | ME00376B (me) |
| MX (1) | MXPA05009068A (me) |
| NO (1) | NO332538B1 (me) |
| NZ (1) | NZ542498A (me) |
| PL (1) | PL226417B1 (me) |
| PT (1) | PT1599478E (me) |
| RS (1) | RS52386B (me) |
| SI (1) | SI1599478T1 (me) |
| TW (1) | TWI313600B (me) |
| UA (1) | UA80743C2 (me) |
| WO (1) | WO2004076454A1 (me) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1632493A1 (de) | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006021548A1 (de) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CA2629249C (en) | 2005-11-11 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Combination treatment of cancer comprising egfr/her2 inhibitors |
| AU2012256410B2 (en) * | 2006-02-08 | 2016-04-28 | Boehringer Ingelheim International Gmbh | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation |
| US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| ATE479434T1 (de) | 2006-02-14 | 2010-09-15 | Vertex Pharma | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine |
| CN101448830A (zh) * | 2006-05-19 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 作为抗增殖剂的二氢碟啶化合物 |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| US8129387B2 (en) * | 2006-12-14 | 2012-03-06 | Vertex Pharmaceuticals Incorporated | Substituted 5,6-dihydroimidazo[1,5-F]pteridines useful as protein kinase inhibitors |
| WO2008079346A1 (en) | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| EP1953163A1 (en) | 2007-02-01 | 2008-08-06 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pteridinone derivatives as PI3-kinases inhibitors |
| EP2185559A1 (en) * | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
| CN101878216B (zh) | 2007-09-28 | 2013-07-10 | 西克拉塞尔有限公司 | 作为蛋白激酶抑制剂的嘧啶衍生物 |
| WO2009067547A1 (en) * | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| EP2215091B1 (en) * | 2007-12-04 | 2016-03-30 | Nerviano Medical Sciences S.r.l. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
| GB0807452D0 (en) * | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | PLK inhibitors |
| EP2318412B1 (en) * | 2008-06-23 | 2013-08-14 | Vertex Pharmceuticals Incorporated | Protein kinase inhibitors |
| WO2010021750A2 (en) | 2008-08-21 | 2010-02-25 | The Johns Hopkins University | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
| WO2010025073A1 (en) * | 2008-08-28 | 2010-03-04 | Takeda Pharmaceutical Company Limited | Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| UY32306A (es) | 2008-12-09 | 2010-07-30 | Gilead Sciences Inc | Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos |
| EP2379559B1 (en) * | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| WO2011031965A1 (en) | 2009-09-14 | 2011-03-17 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| SG179207A1 (en) | 2009-09-25 | 2012-04-27 | Vertex Pharma | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| MX2012003484A (es) | 2009-09-25 | 2012-04-20 | Vertex Pharma | Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa. |
| NZ599549A (en) | 2009-10-26 | 2013-11-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| EP2325185A1 (en) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Plk inhibitor |
| CN102762568A (zh) * | 2009-12-23 | 2012-10-31 | 伊兰药品公司 | 作为polo样激酶的抑制剂的蝶啶酮 |
| US20120329803A1 (en) * | 2010-02-17 | 2012-12-27 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| CN102190669A (zh) * | 2010-03-19 | 2011-09-21 | 江苏恒瑞医药股份有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| US8546566B2 (en) * | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| RU2013132681A (ru) | 2010-12-16 | 2015-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы репликации вирусов гриппа |
| US20130131069A1 (en) | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| CN103998036B (zh) | 2011-10-19 | 2017-05-31 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
| US9351974B2 (en) | 2011-11-10 | 2016-05-31 | OSI Pharmaceuticals, LLC | Substituted pteridinones for the treatment of cancer |
| BR112014013332B1 (pt) | 2011-12-02 | 2022-09-06 | Signal Pharmaceuticals, Llc | Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso |
| JP5807750B2 (ja) * | 2012-01-05 | 2015-11-10 | トヨタ自動車株式会社 | 締付装置及び締付方法 |
| US9006226B2 (en) | 2012-02-23 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Dihydropteridinones I |
| US8865716B2 (en) | 2012-02-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Dihydropteridinones II |
| CN104271159B (zh) | 2012-02-24 | 2017-11-28 | 西格诺药品有限公司 | 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US20140154304A1 (en) | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
| SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| EP2958919B1 (en) * | 2013-02-21 | 2019-05-22 | Boehringer Ingelheim International GmbH | Dihydropteridinones i |
| JP6072308B2 (ja) * | 2013-02-21 | 2017-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンｉｉ |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| EP3549940A1 (en) | 2013-04-17 | 2019-10-09 | Signal Pharmaceuticals, LLC | Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| MY189663A (en) | 2013-04-17 | 2022-02-23 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
| PT3068776T (pt) | 2013-11-13 | 2019-08-26 | Vertex Pharma | Inibidores da replicação de vírus da gripe |
| HUE038820T2 (hu) | 2013-11-13 | 2018-11-28 | Vertex Pharma | Eljárás influenzavírusok replikációjának inhibitorai elõállítására |
| KR20160111520A (ko) * | 2014-01-31 | 2016-09-26 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| EP3099693A4 (en) | 2014-01-31 | 2017-08-16 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| CN104003989B (zh) | 2014-05-26 | 2015-11-11 | 苏州明锐医药科技有限公司 | 伏拉塞替及其中间体的制备方法 |
| SI3166607T1 (sl) | 2014-07-11 | 2023-01-31 | Gilead Sciences, Inc. | Modulatorji toličnih receptorjev za zdravljenje HIV-a |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2016010886A1 (en) | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| WO2016022970A1 (en) * | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
| CN110305133A (zh) | 2014-09-16 | 2019-10-08 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
| CN107074860B (zh) | 2014-09-16 | 2022-07-15 | 吉利德科学公司 | 制备toll样受体调节剂的方法 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| WO2017079563A1 (en) | 2015-11-06 | 2017-05-11 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
| CR20180336A (es) | 2015-11-25 | 2018-08-06 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos |
| CN105801582A (zh) * | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
| DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
| CN106977584B (zh) * | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| AU2018392805A1 (en) | 2017-12-22 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | NEK inhibitors and methods of use |
| WO2019145410A1 (en) | 2018-01-25 | 2019-08-01 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| CN110343109B (zh) * | 2019-08-21 | 2021-11-23 | 郑州大学 | 一种二氢蝶啶酮-磺酰胺类衍生物及其药学上可接受的盐、其制备方法及其应用 |
| WO2023196943A1 (en) | 2022-04-08 | 2023-10-12 | Inhibrx, Inc. | Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy |
| WO2026025042A1 (en) * | 2024-07-26 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | P53 targeting compounds and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003509425A (ja) * | 1999-09-15 | 2003-03-11 | ワーナー−ランバート・カンパニー | キナーゼ阻害剤としてのプテリジノン |
| WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| UY27427A1 (es) * | 2001-09-04 | 2003-03-31 | Boehringer Ingelheim Pharma | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos |
-
2003
- 2003-02-26 DE DE50307267T patent/DE50307267D1/de not_active Expired - Lifetime
- 2003-02-26 CA CA2517020A patent/CA2517020C/en not_active Expired - Fee Related
- 2003-02-26 ES ES03816028T patent/ES2287583T3/es not_active Expired - Lifetime
- 2003-02-26 AT AT03816028T patent/ATE361924T1/de active
- 2003-02-26 ME MEP-2008-588A patent/ME00376B/me unknown
- 2003-02-26 MX MXPA05009068A patent/MXPA05009068A/es active IP Right Grant
- 2003-02-26 KR KR1020057015805A patent/KR100983462B1/ko not_active Expired - Fee Related
- 2003-02-26 CN CNB038260298A patent/CN100537570C/zh not_active Expired - Fee Related
- 2003-02-26 AU AU2003215591A patent/AU2003215591B2/en not_active Ceased
- 2003-02-26 RS YU20050648A patent/RS52386B/sr unknown
- 2003-02-26 HR HRP20050735AA patent/HRP20050735B1/hr not_active IP Right Cessation
- 2003-02-26 CN CNA200810002434XA patent/CN101200457A/zh active Pending
- 2003-02-26 PT PT03816028T patent/PT1599478E/pt unknown
- 2003-02-26 EA EA200501222A patent/EA008778B1/ru not_active IP Right Cessation
- 2003-02-26 EP EP03816028A patent/EP1599478B1/de not_active Expired - Lifetime
- 2003-02-26 BR BRPI0318145-6A patent/BR0318145A/pt not_active Application Discontinuation
- 2003-02-26 WO PCT/EP2003/001935 patent/WO2004076454A1/de not_active Ceased
- 2003-02-26 DK DK03816028T patent/DK1599478T3/da active
- 2003-02-26 JP JP2004568646A patent/JP3876265B2/ja not_active Expired - Lifetime
- 2003-02-26 PL PL378168A patent/PL226417B1/pl unknown
- 2003-02-26 NZ NZ542498A patent/NZ542498A/en not_active IP Right Cessation
- 2003-02-26 SI SI200330867T patent/SI1599478T1/sl unknown
- 2003-02-26 UA UAA200509021A patent/UA80743C2/uk unknown
- 2003-03-03 TW TW092104404A patent/TWI313600B/zh not_active IP Right Cessation
-
2005
- 2005-08-22 IL IL170419A patent/IL170419A/en not_active IP Right Cessation
- 2005-09-23 NO NO20054414A patent/NO332538B1/no not_active IP Right Cessation
-
2007
- 2007-07-24 CY CY20071100981T patent/CY1106752T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2517020A1 (en) | Dihydropteridinones, method for the production and use thereof in the form of drugs | |
| CA2971110C (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| JP5400804B2 (ja) | 慢性痛症に活性のある窒素含有二環式化合物 | |
| NZ788543A (en) | Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| RU2637309C2 (ru) | Способ получения соединений тиенопиримидина | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| HRP20040178B1 (hr) | Derivati piperidina kao antagonisti nmda receptora | |
| CA2458699A1 (en) | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments | |
| TNSN07361A1 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| EP3452480A1 (en) | Substituted pyrrolo[1,2- ]triazines and related compounds and their use in the treatment of medical disorders | |
| ZA202306437B (en) | Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| GEAP202516737A (en) | Compounds for treating cancer | |
| MX2025002452A (es) | Serie de compuestos heterociclicos puenteados que contienen nitrogeno y metodo de preparacion de los mismos | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| MX2025000635A (es) | Compuestos cíclicos y métodos de utilización de estos | |
| JP2012506908A5 (me) | ||
| MXPA05010020A (es) | Derivados de oxamida. | |
| NZ592766A (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| WO2021062168A1 (en) | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment | |
| ZA202405279B (en) | Heteroaryl derivative and use thereof | |
| PL1789044T3 (pl) | Fenyloaminopirydyny i fenyloaminopirazyny | |
| TH57403B (th) | ไดไฮโดรพเทอริดิโนนชนิดใหม่,กรรมวิธีสำหรับการเตรียมสาร?เหล่านี้และการใช้สารเหล่านี้เป็นยา | |
| TH102360A (th) | ไดไฮโดรพเทอริดิโนนชนิดใหม่,กรรมวิธีสำหรับการเตรียมสาร?เหล่านี้และการใช้สารเหล่านี้เป็นยา |